ONASEMNOGENE ABEPARVOVEC

Brand name:

• Zolgensma®

Pharmaceutical company:

Novartis Pharmaceuticals Austraila Pty Limited

Condition/indication:
(therapeutic use)

• Spinal muscular atrophy (SMA)

PBAC Submission type:

New listing (Matters outstanding)

Comment:

--

Public Summary Document:

PBAC Public Summary Documents – May 2021

Related medicines:

• ONASEMNOGENE ABEPARVOVEC

Submission received for:

May 2021 PBAC meeting

Opportunity for consumer comment:

--

PBAC meeting:

Held on 07/05/2021

PBAC outcome published:

Deferred (see PBAC Outcomes)

Lodgement of required documentation:

Not applicable

Agreement to listing arrangements:

Not applicable

Government processes:

Not applicable

Medicine listed on the PBS:

Not applicable

---